Retinal Vein Occlusion Treatment Market Will Generate Booming Growth Opportunities to 2033

The global Retinal Vein Occlusion Treatment market is expected to be valued US$ 2.3 billion in 2023, with a compound annual growth rate (CAGR) of 5.9% from 2023 to 2033, reaching US$ 4.7 billion. One of the most prevalent retinal vascular problems in the elderly is retinal vein occlusion, which affects persons over the age of 65. The risk of retinal vein blockage increases with age. As the geriatric population grows, the prevalence of retinal vein blockage is expected to climb.

Because of numerous improved medical facilities, a growth in the prevalence of eye disorders, technological advancements, and an ageing population, North America held a large percentage of the worldwide retinal vein occlusion market in 2022. Between 2023 and 2033, the Asia Pacific retinal vein occlusion market is expected to develop at a 6.5% CAGR. Rising ocular illness prevalence in Asia Pacific, particularly in China, Singapore, Indonesia, and other Southeast Asian countries, as well as rising health expenditures, are predicted to fuel East and South Asian market expansion from 2023 to 2033. Europe is predicted to have the second-largest market share throughout the forecast years. The region's retinal vein occlusion market is being propelled forward by an ageing population and higher healthcare spending.

In terms of global retinal vein occlusion medications revenue, the branch retinal vein occlusion sector gained the highest in 2022. This segment is expected to dominate the market as the prevalence of high blood pressure, cardiovascular disease, and glaucoma rises.

Market Competition

Key players in the Retinal Vein Occlusion Treatment market are AbbVie, Roche, Regeneron Pharmaceuticals, Taiwan Liposome Company, Aerie Pharmaceuticals, Graybug Vision, Kodiak Sciences Inc., Chugai Pharmaceuticals, and Novartis AG among others.

Get More Details@ https://www.futuremarketinsights.com/reports/retinal-vein-occlusion-treatment-market

Key Segments Profiled in the Retinal Vein Occlusion Treatment Industry Survey

By Drug Class:

  • Ranibizumab
  • Dexamethasone
  • Aflibercept
  • Bevacizumab

By Type:

  • Central Retinal Vein Occlusion
  • Branch Retinal Vein Occlusion

By Diagnosis:

  • Optical Coherence Tomography
  • Fundoscopic Examination
  • Fluorescein Angiography

By End User:

  • Hospitals
  • Research and Academics
  • Specialty Clinics

Comments

Post a Comment

Popular posts from this blog

Targeted Therapies for Sandhoff Disease | Assessing the Global Market Landscape

Image
The global Sandhoff Disease Therapeutics Market Size is expected to be worth US$ 10 million in 2023 and US$ 17.91 million by 2033, with a CAGR of 6% from 2023 to 2033. From 2018 to 2022, the Sandhoff Disease Treatments market increased at a 4% CAGR. According to the most recent studies, Sandhoff sickness is a rare disorder that affects 1 in 1,000,000 people. The rising demand for these medications is projected to spur the discovery of novel therapies, propelling the market forward in the coming years. Gene therapy is being investigated as a potential treatment for Sandhoff disease. The therapy restores the ability to break down GM2 ganglioside by delivering a functional copy of the missing enzyme into the patient's cells. This has the potential to reduce or stop disease progression while also improving patient quality of life. Key Takeaways from the Market Study   The Sandhoff Disease Therapeutics market increased at a 4% CAGR from 2018 to 2022. From 2023 to 2033, the global Sandh
Read more

A Safer Tomorrow | Emerging Trends in Hospital-Acquired Infection Control Market

Image
According to Future Market Insights' recently released Hospital-acquired Infection Control Market analysis report, global Hospital-acquired Infection Control sales in 2023 are expected to be US$ 6.5 billion. The market is expected to increase at a CAGR of 7% between 2023 and 2033, reaching $12.7 billion by 2033. Hospitals and intensive care units are predicted to create significant income in the market, with a CAGR of 7.6%. The occurrence of hospital-acquired infections, increasing proportion of surgical procedures, growing geriatric population and increasing prevalence of chronic diseases, technological advancements in sterilisation equipment, and growing awareness of environmental and personal hygiene are the key factors driving the Hospital-acquired infection control market. The increased use of e-beam sterilisation, as well as the reintroduction of ethylene oxide sterilisation, is predicted to increase demand for hospital-acquired infection management. The percentage of treatm
Read more

Transforming Trauma | Emerging Therapies and Interventions in Post-Traumatic Stress Disorder Treatment Market

Image
According to Future Market Insights, the Post-Traumatic Stress Disorder (PTSD) Treatment Market Sales would grow at a 5% CAGR between 2023 and 2033. By 2033, the global market for post-traumatic stress disorder (PTSD) therapy is expected to reach US$ 27.37 billion. The market's growth might be attributed to the increased prevalence of PTSD globally. According to the National Centre for PTSD, approximately 7-8% of the US population will develop PTSD at some point in their lives, with greater percentages among military veterans and persons who have experienced sexual assault or other types of trauma. The COVID-19 pandemic has also been highlighted as a possible cause of PTSD, with healthcare workers, first responders, and people immediately impacted by the virus being especially vulnerable. In addition, there is a growing emphasis on using digital therapies and other non-pharmacological techniques to treat PTSD. For example, virtual reality exposure treatment (VRET) has shown potent
Read more